UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte - PubMed
7 hours ago
- #MASH
- #p38 MAPK
- #UBQLN1
- UBQLN1 inhibition reduces MASH progression by downregulating the SIKE/p38 MAPK pathway in hepatocytes.
- UBQLN1 is upregulated in MASH patients and mouse models, correlating with hepatic lipid deposition.
- Knockdown of UBQLN1 reduces hepatic steatosis, inflammation, and fibrosis in MASH mice.
- UBQLN1 promotes lipid accumulation via ubiquitin-mediated degradation of SIKE, activating the p38 MAPK pathway.
- RBC-EVs loaded with UBQLN1 siRNA effectively mitigate lipid accumulation and improve MASH progression in vivo.
- The study identifies the UBQLN1-SIKE-p38 MAPK axis as critical in MASH pathogenesis.
- A novel RBC-EVs-targeted delivery system is developed for MASH therapy.